1-3 of 3
Machiko Shiroishi
Close
Sort by
Journal Articles

Anti-Tumor Effect of the EZH1/2 Dual Inhibitor Valemetostat Against Diffuse Large B-Cell Lymphoma Via Modulation of B-Cell Receptor Signaling and c-Myc Signaling Pathways

Yasuhiro Hama, PhD, Toshihiro Banjo, PhD, Daisuke Honma, PhD, Yoshimi Takata, Emi Nosaka, Machiko Shiroishi, Kenji Watanabe, Yuka Yamamoto, Tsuyoshi Hirata, Rika Nakano, Koichiro Inaki, PhD, Hiroki Goto, PhD, Yusuke Totoki, PhD, Miki Kataoka, Kyungtaek Lim, PhD, Chisa Wada, Eiji Kumazawa, PhD, Shinji Tsutsumi, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4642.
https://doi.org/10.1182/blood-2019-125436
Published: 2019
Journal Articles

DS-3201, a Potent EZH1/2 Dual Inhibitor, Demonstrates Antitumor Activity Against Non-Hodgkin Lymphoma (NHL) Regardless of EZH2 Mutation

Daisuke Honma, PhD, Emi Nosaka, Machiko Shiroishi, Yoshimi Takata, Yasuhiro Hama, Yuka Yamamoto, Nobuaki Adachi, PhD, Dai Maruyama, MD PhD, Kensei Tobinai, MD PhD, Takashi Ishida, MD PhD, Shigeru Kusumoto, MD, Kenji Ishitsuka, MD PhD, Yoshitaka Imaizumi, MD, PhD, Shogo Takeuchi, MD, Kunihiro Tsukasaki, MD PhD, Tomoyuki Fujioka, Jun Watanabe, Osamu Kanno, PhD, Eiji Kumazawa, PhD, Sumiaki Fujitani, MSc, Kazushi Araki, DVM, PhD, Kosaku Fujiwara, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2217.
https://doi.org/10.1182/blood-2018-99-113379
Published: 2018
Journal Articles

Development and Characterization of the Novel Orally Bioavailable EZH1/2 Dual Inhibitor DS-3201

Daisuke Honma, PhD, Nobuaki Adachi, PhD, Osamu Kanno, PhD, Jun Watanabe, Makoto Hirasawa, Emi Nosaka, Machiko Shiroishi, Takeshi Takizawa, Isao Yasumatsu, Takao Horiuchi, PhD, Akira Nakao, PhD, Keisuke Suzuki, Tomonori Yamasaki, Katsuyoshi Nakajima, Miho Hayakawa, Takanori Yamazaki, Kazushi Araki, D.V.M., PhD, Kosaku Fujiwara, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2073.
https://doi.org/10.1182/blood.V130.Suppl_1.2073.2073
Published: 2017